Xeltis Announces Latest Results from aXess Trials to be Presented at 46th Annual Charing Cross Symposium Two key presentations by leading KOLs highlight positive results from aXess trials in adult patients with end-stage renal disease who need vascular access to hemodialysisaXess is a restorative arteriovenous.
Outstanding 12-Month First-In-Human Data From Xeltis' Axess Hemodialysis Vascular Conduit Trial Presented At Veithsymposium 2023 menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
Outstanding 12-month first-in-human data from Xeltis’ aXess hemodialysis vascular conduit trial presented at VEITHsymposium 2023 aXess demonstrated exceptional patency rates and no infections to date EINDHOVEN, The Netherlands – 17 November 2023, Xeltis, a leading developer of transformative implants that enable the natural creation of living and long-lasting vessels, announces outstanding 12-month data from its first-in-human (FIH) aXess vascular conduit trial (NCT04898153). The data was presen
Xeltis secures additional €12.5 million from European Innovation Council Fund in final close of D2 financing streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.